The current medical consensus, reflected in obesity medicine guidelines from organizations such as the American Gastroenterological Association and Obesity Medicine Association, treats obesity as a chronic disease requiring long-term pharmacological management in most cases, similar to hypertension or hyperlipidemia
Glucagon-like peptide-1 (GLP-1) agonists represent a class of medications that mimic the action of the naturally occurring incretin hormone GLP-1
GLP-1 Receptor Agonists vs
These novel drug delivery systems and technologies can not only improve the in vivo stability and bioavailability of peptide drugs, but also achieve sustained or controlled release to significantly enhance their therapeutic effects
Maybe youve heard the (demoralizing) statistic that, on average, 95% of lost weight is regained after five years
And some providers recommend allowing up to 12 weeks of treatment to see a response